Wells Fargo upgraded Regulus (RGLS) to Overweight from Equal Weight with a price target of $6, up from $3.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Regulus Announces Positive Phase 1b Study Results
- Regulus’ farabursen shows efficacy in Phase 1b kidney disease trial
- Promising Developments and Strategic Positioning Drive Buy Rating for Regulus Therapeutics
- Regulus Therapeutics Reports Positive Trial Results and Financials
- Buy Rating for Regulus Based on Promising Phase 1b Results and Strong Financial Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue